KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novartis Ag (NVS) Retained Earnings (2017 - 2025)

Novartis Ag's Retained Earnings history spans 9 years, with the latest figure at $45.4 billion for Q4 2025.

  • For Q4 2025, Retained Earnings rose 4.87% year-over-year to $45.4 billion; the TTM value through Dec 2025 reached $45.4 billion, up 4.87%, while the annual FY2025 figure was $45.4 billion, 4.87% up from the prior year.
  • Retained Earnings for Q4 2025 was $45.4 billion at Novartis Ag, up from $43.3 billion in the prior quarter.
  • Across five years, Retained Earnings topped out at $66.8 billion in Q4 2021 and bottomed at $43.3 billion in Q4 2024.
  • The 5-year median for Retained Earnings is $45.9 billion (2023), against an average of $52.0 billion.
  • The largest annual shift saw Retained Earnings grew 19.85% in 2021 before it dropped 21.63% in 2023.
  • A 5-year view of Retained Earnings shows it stood at $66.8 billion in 2021, then decreased by 12.36% to $58.5 billion in 2022, then decreased by 21.63% to $45.9 billion in 2023, then decreased by 5.62% to $43.3 billion in 2024, then increased by 4.87% to $45.4 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Retained Earnings are $45.4 billion (Q4 2025), $43.3 billion (Q4 2024), and $45.9 billion (Q4 2023).